Skip to main content
. 2020 Sep 25;14(1):100873. doi: 10.1016/j.tranon.2020.100873

Fig. 5.

Fig. 5

Modeled absorbed dose profiles of assumed spherical microscopic tumors of various diameters exposed to intraperitoneally administered 211At-farletuzumab. Dashed lines indicate modeled results for microtumors in mice exposed to amounts presented in the current work. Solid lines are model results for microtumors in patients exposed to clinically relevant amounts.